Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data, shared through one oral and two poster sessions, focused on two key candidates: TNX-1700 and TNX-4700. These findings underscore Tonix’s efforts to expand its pipeline beyond CNS disorders into oncology, leveraging its expertise in immunology.
TNX-1700, a novel biologic, demonstrated the ability to reduce inflammation and tumor progression in preclinical models of gastric cancer. The data also showed favorable pharmacokinetics, suggesting it could be a viable therapeutic option. Gastric cancer remains a significant unmet medical need, with limited effective treatments, making these findings particularly relevant. Tonix’s approach targets the tumor microenvironment, aiming to modulate immune responses to improve outcomes.
For TNX-4700, the company reported promising in vitro activity targeting BTLA (B- and T-lymphocyte attenuator), a checkpoint receptor. TNX-4700 is designed as a cancer immunotherapy candidate that could be used alone or in combination with other checkpoint inhibitors, such as anti-PD-1 agents. By targeting BTLA, Tonix aims to enhance anti-tumor immune responses and overcome resistance to existing immunotherapies.
The presentations at AACR, a premier cancer research conference, highlight Tonix’s commitment to advancing its immuno-oncology pipeline. The company is known for its CNS portfolio, including TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, and is now translating its immunology expertise into cancer therapies. The full press release is available at https://ibn.fm/Oly6o.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company with a focus on CNS and immunology treatments in areas of high unmet need. Its flagship product, TONMYA, is the first new treatment for fibromyalgia in over 15 years. The company also markets acute migraine products Zembrace SymTouch and Tosymra. Beyond oncology, Tonix is evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, and advancing TNX-2900 for Prader-Willi syndrome. Its immunology pipeline includes TNX-4800 for Lyme disease prophylaxis and TNX-1500, a CD40 ligand inhibitor for kidney transplant rejection.
The latest news and updates on TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. These developments are part of Tonix’s broader strategy to address significant medical needs through innovative science.
